Lv73
3720 积分 2024-05-31 加入
The AUTACE That Degrades KRAS and Engages CD8 + T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors
1个月前
已完结
T-cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial
2个月前
已完结
T-cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial
2个月前
已关闭
Engineered TCR-T Cells Secreting IFNα/Anti-PD-L1 Potentiate Endogenous Immunity to Synergistically Bolster the Efficacy Against Solid Tumors
2个月前
已完结
Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation
3个月前
已关闭
Development of Regulation and Policy for Cell Therapies in China
4个月前
已完结
HBV antigen as a tumour antigen in adoptive TCR-T cell therapy for HBV-related HCC: rationale and clinical effectiveness
6个月前
已完结
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma
8个月前
已完结
Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy
8个月前
已完结
Structures of butyrophilin multimers reveal a plier-like mechanism for Vγ9Vδ2 T cell receptor activation
10个月前
已完结
皖公网安备34019202002308
